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Abstract 
The relationship between transforming rowth factor a (TGFa)-induced cell proliferation and prostaglandin synthesis was investi- 
gated using growth-arrested human keratinocytes of the HaCaT line. Depending on the TGFa concentration, the stimulation of DNA 
synthesis (5-fold) was found to be either insensitive (at < 10 ng/ml TGF~) or sensitive (at > 20 ng/ml TGFa) to inhibition by both 
indomethacin, an inhibitor of prostaglandin synthases (PGHS) 1 and 2 and the PGHS 2-specific inhibitor NS-398. Indomethacin-effected 
inhibition did not correlate with cytotoxicity and was restricted to a narrow time window after growth factor administration. The 
indomethacin- and NS-398-sensitive mitogenic effect of TGFa correlated with an early increase of arachidonic acid release and 
prostaglandin (PGE 2, PGF2,) synthesis, whereas the PGHS inhibitor-insensitive TGFa effect did not. TGFa-induced prostaglandin 
synthesis was due to a growth factor-induced PGHS-2 activity as indicated by its suppression by NS-398. However, attempts to overcome 
the PGHS inhibitor-dependent suppression of TGFa-induced DNA synthesis by adding prostaglandins (E l, E 2, F 2 ~, G 2) to the cultures 
proved to be unsuccessful. Thus, TGFa-induced synthesis of prostaglandins seems not to be involved in the mediation of the mitogenic 
effect of the growth factor on human keratinocytes in culture. 
Keywords: Transforming growth factor a; Prostaglandin; Keratinocyte; Mitogenic signaling 
I. Introduction 
The skin responds to chemical or mechanical irritation 
by hyperplastic transformation, i.e., an inflammatory reac- 
tion accompanied by cellular hyperproliferation leading to 
epidermal hyperplasia [1]. Hyperplastic transformation pro- 
vides a condition for the defence against microbial infec- 
tions and wound-healing but also plays a role in patho- 
physiological processes uch as skin tumor promotion. The 
response is certainly controlled by a wide variety of en- 
dogenous factors such as cytokines and other 'proin- 
flammatory mediators', most of which are probably re- 
leased from keratinocytes upon activation by an exogenous 
stimulus [2]. The interactions between these different fac- 
tors are far from being understood. 
Abbreviations: TGFot, transforming growth factor a; EGF, epidermal 
growth factor; PGE 2, prostaglandin E2; PGF 2 ~, prostaglandin F 2~,; PGG 2, 
prostaglandin G2; PBS, phosphate-buffered saline; MTT, 3-[4,5-dimethyl- 
thiazol-2-yl]-2,5,diphenyltetrazolium bromide; [3H]TdR, [methyl- 
3 H]thymidine. 
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In mouse skin the release of arachidonic acid and 
prostaglandin formation have been found to rank among 
the most rapid responses to irritation. As shown by experi- 
ments with inhibitors of prostaglandin synthesis, epidermal 
hyperproliferation depends critically on prostaglandin E 2 
(PGE 2) [3,4]. Since prostaglandin application in the ab- 
sence of an irritant does not result in hyperplastic develop- 
ment of mouse epidermis, prostaglandins seem to play a 
permissive role rather than to mediate the tissue response 
[5]. The molecular mechanism of the prostaglandin effect 
is not known. 
Among the many other factors released from activated 
keratinocytes, TGFa has been shown to fulfill an impor- 
tant role as a 'wound hormone' and an autocrine growth 
factor for keratinocytes. Biopsies of human epidermis and 
primary human keratinocytes were shown to express TGFa 
at the m-RNA and protein level [6]. TGFa autocatalyti- 
cally induced TGFa-gene expression in keratinocytes and 
was found in abundance in benign and malignant hyper- 
proliferative skin diseases [7,8]. Moreover, TGFa has been 
shown to induce proliferation of epidermal keratinocytes in
culture [9,10]. In epidermis, TGFa rather than EGF is 
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thought o be the cognate EGF-receptor ligand [11]. The 
signaling cascade thus initiated and finally leading to DNA 
synthesis has recently been elucidated in more detail [12]. 
Lately we reported that TGFa activates phospholipase 
A 2 in mouse keratinocytes in vitro and thus induces the 
release of arachidonic acid and prostaglandin synthesis 
[13]. The question arises as to whether prostaglandins 
mediate TGFa function (or vice versa) or whether both 
factors act independently of each other in inducing epider- 
mal hyperproliferation. Here we report on experiments 
which indicate that the mitogenic action of TGFa on 
human keratinocytes in culture is independent of the growth 
factor-induced synthesis of prostaglandins. 
compounds was replaced by fresh medium containing 0.5 
mg/ml 3-[4,5-dimethylthiazol-2-yl]-2,5, diphenyltetra- 
zolium bromide (MTT) and the cells were incubated for a 
further 30 rain. Thereafter the cultures were washed twice 
with PBS. Only in viable cells which contain active mito- 
chondria the yellow MTT dye is reduced by mitochondrial 
succinic dehydrogenase to black formazan. The formazan 
was eluted from the cells with 1 ml of acidified isoamylal- 
cohol and the optical density was determined by means of 
an ELISA reader (Biotek E 312) at 570 nm. The concentra- 
tion of MTT-formazan is proportional to the number of 
viable cells. 
2.4. DNA-labeling 
2. Materials and methods 
2.1. Materials 
The prostaglandins E 2 and F2a were obtained from 
Paesel, Frankfurt (Germany), and PGG 2 from Biomol, 
Hamburg (Germany). TGFa was provided by Saxon Bio- 
chemicals, Hannover (Germany), NS-398 by Cayman 
Company Ann Arbor, Michigan (USA), and indomethacin 
by Sigma, Munich (Germany). [l-14C]Arachidonic acid 
(2.16 GBq/mmol) and [methyl-3H]thymidine (925 
GBq/mmol) were products of Amersham-Buchler, Braun- 
schweig (Germany). ELISA kits for the prostaglandin as- 
say were obtained from IBL, Hamburg (Germany) and 
silica gel-60 TLC plates from Merck, Darmstadt 
(Germany). All culture media were purchased from 
Biochrom, Berlin (Germany) and serum from GIBCO, 
Grand Island, NY. 
2.2. Cell culture 
HaCaT keratinocytes [14] were kindly provided by Prof. 
N.E. Fusenig, DKFZ, Heidelberg. The cells (passages 20- 
35) were grown in Eagle's minimal essential medium with 
a 4-fold concentration of amino acids and vitamins (4 × 
MEM) supplemented with 2.5% fetal calf serum and an- 
tibiotics (penicillin, 100 IU/ml, streptomycin 100 /xg/ml) 
under a humidified atmosphere (air/CO 2, 95:5 mol%) at 
37°C. After 3 days the medium was replaced by 4 × MEM 
supplemented with 0.25% fetal calf serum (low serum 
medium) and the cells were incubated for 2 days. By 
means of fuorescence-activated cell sorting and 
[3H]thymidine incorporation, cells were found to be ar- 
rested in the Go-Gl-phase. For the experiments fresh low 
serum medium containing the test compounds was added 
to the cells at 80-90% confluency. 
One hour before the end of incubation with test com- 
pounds, the cells were labeled with 7.5 /zCi/ml [3H]TdR. 
Thereafter, the medium was removed and the cells were 
washed with PBS and stored at -20°C. The cell monolay- 
ers were processed according to Fiirstenberger t al. [16] 
and the DNA concentration was determined according to 
Burton [17]. 
2.5. Prelabeling of  cells with and extraction of  arachidonic 
acid 
Subconfluent cultures were incubated with [1- 
14C]arachidonic acid (0.2 /xCi/ml low serum medium) for 
16 h, i.e., to equilibrium labeling of phospholipids. The 
radioactive medium was then replaced by fresh low serum 
medium containing the test compounds. After a given time 
period the medium was removed and processed either 
immediately or stored at -20°C. Arachidonic acid was 
extracted from the medium according to Fiirstenberger t
a|. [16] and separated by thin-layer chromatography ac- 
cording to Flower and Blackwell [18]. Radioactivity was 
determined by means of a TLC-linear analyzer (Berthold 
LB 2842, Wildbad, Germany). 
2.6. Prostaglandin assay 
After incubation of the cells with the test substances, 
the medium was collected and extracted according to 
Fiirstenberger tal. [16]. PGE 2 or PGF2~ were determined 
by an immunoenzymometric assay [19] carried out accord- 
ing to the instructions of the supplier (IBL, Hamburg, 
Germany). Optical densities were measured by means of 
an ELISA reader at 405 nm (Biotek E 312). 
3. Results 
2.3. Viability test 3.1. TGFa-induced keratinocyte proliferation 
Cell viability was determined using the MTT-reduction 
assay [15]. For this purpose the medium containing the test 
When growth-arrested HaCaT cells were treated with 
TGFa in 0.25% serum medium, a dose-dependent i crease 
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Fig. 1. Effect of TGFa on DNA-labeling in HaCaT cells. Growth-arre- 
sted HaCaT cells were treated with increasing concentrations of TGFot 
for 31 h. One-h pulse-labeling of DNA was carried out after 30 h as 
described in Section 2. Each peint is the mean+_S.E, of 3 independent 
experiments performed in triplicate. 
of [3H]TdR incorporation i to DNA was observed around 
30 h after addition of the growth factor (Fig. 1). Maximal 
stimulation (5-fold) was achieved with 10-25 ng/ml. 
Higher concentrations of TGFa were less effective. 
Fig. 2 depicts the time course of DNA-labeling upon 
treatment of the cells with 25 ng/ml  TGFa as compared 
to control cells which obtained only low serum medium. 
The medium change had a moderate stimulatory effect 
which was strongly augmented by TGFa leading to a peak 
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Fig. 3. Effect of the duration of TGFa treatment on DNA-labeling. 
Growth-arrested HaCaT cells were either treated with TGFc~ (25 ng/ml;  
hatched columns) or bidistilled water (control; empty columns) for the 
time periods indicated. Thereafter the cells were incubated with condi- 
tioned media from parallel cultures without the mitogen. After 30 h 
DNA-labeling was carried out as described in Section 2. Each value 
represents the mean4-S.E, of 2 independent experiments performed in 
triplicate. 
at about 30 h. To elicit a significant increase of DNA- 
labeling after 30 h, the cultures had to be left in contact 
with TGFce for only 1 h (Fig. 3). This indicates rather 
early events to be critical for TGFce-induced mitogenesis. 
3.2. Stimulation of arachidonic acid release and prosta- 
glandin synthesis by TGFc~ 
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Fig. 2, Time course of TGFc~-induced DNA-labeling in HaCaT cells. 
Growth-arrested HaCaT cells were treated with TGFa (25 ng/ml;  O)  or 
bidistilled water (control; ©) at zero time and DNA was isolated at the 
times indicated. One h pulse-labeling of DNA was performed as de- 
scribed in Section 2. Each point is the mean_+ S.E. of 3 independent 
experiments performed in triplicate. 
TGFa was found to stimulate the release of [1- 
14C]arachidonic acid from prelabeled cells quite rapidly, 
i.e., within 30 min (Fig. 4). The extracellular content of 
labeled arachidonic acid decreased at later time points 
probably due to re-utilization of the fatty acid by the cells. 
The inset of Fig. 4 shows the dose dependence of the 
TGFa-induced arachidonic acid release. With TGFc~ con- 
centrations > 20 ng/ml,  arachidonic acid production was 
strongly stimulated, whereas with < 10 ng/ml  of TGFa a 
significant stimulation could not be measured. The major 
prostaglandins generated in HaCaT cells were PGE 2 and 
PGF2,. As shown in Fig. 5a, accumulation of PGE 2 
followed a time course different from that of arachidonic 
acid, reaching a plateau within 4 and 9 h of TGFa 
treatment and declining thereafter, presumably due to con- 
version of PGE 2 to PGF2~ [20]. This assumption was 
supported by the time course of PGF 2. accumulation i  
the medium of TGFa-treated cells: while in the beginning 
the rates of PGF2, and PGE 2 release were quite similar, 
PGF 2 ~ did not disappear but accumulated for up to 25 h 
(Fig. 5b). PGE 2 biosynthesis was inhibited in a dose-de- 
pendent manner by both indomethacin and NS-398 (Table 
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DNA-labeling stimulated with 10 ng/ml  TGFa or less 
was not impaired by the inhibitor. The dose dependence of
TGFe-induced prostaglandin production correlated with 
that of indomethacin sensitivity: at a TGFa concentration 
< 10 ng/ml, no increase of the PGF2~ level in the 
medium was observed, whereas at doses of > 25 ng/ml  
TGFc~ a strong induction of PGF2~ formation occurred 
(Fig. 7). Similar results were obtained for PGE 2 (not 
shown). These data indicated two pathways of TGFa-in- 
duced mitogenic stimulation in HaCaT cells: one appeared 
to be dependent and the other independent of prostaglandin 
synthesis. They also confirmed that the inhibition by indo- 
methacin was not due to cytotoxicity, since a cytotoxic 
effect should not depend on the TGFa concentration. 
hours  
Fig. 4. Effect of TGFc~ on the release of arachidonic acid from growth- 
arrested HaCaT cells. Cells prelabeled with [1-14C]arachidonic a id were 
treated with (0 )  or without (v )  TGFc~ (25 ng/ml) in fresh culture 
medium at zero time. At the times indicated, the arachidonic acid content 
of the supernatants was determined as described in Section 2. The inset 
shows the dependence of arachidonic acid release on the TGFe dose as 
measured 30 min after treatment. Each point is the mean_+ S.E. of two 
independent experiments performed in triplicate. 
1), an inhibitor of prostaglandin H synthases (PGHS) 1 and 
2 [21] and a specific PGHS 2 inhibitor [22], respectively. 
3.3. Effects of inhibitors of prostaglandin synthases and 
prostaglandins on TGFot-induced DNA synthesis 
To determine whether prostaglandin release is an essen- 
tial event in TGFa-induced mitogenesis, the effect of 
inhibitors of prostaglandin synthesis was investigated. As 
shown in Fig. 6, indomethacin hibited both the release of 
PGF 2. and DNA synthesis in TGFa-treated HaCaT cells, 
though with different dose dependencies. Thus, the release 
of PGF2~ (and PGE 2, not shown) was already strongly 
inhibited at concentrations of 0.1-10 /zM indomethacin, 
whereas the DNA synthesis was only reduced at concentra- 
tions of 40 /~M. In order to exclude a cytotoxic effect of 
indomethacin, cell viability was measured using the MTT 
reduction assay. No substantial loss of viability was ob- 
served up to 40 /xM and only a slight cytotoxic effect 
became apparent at 100 /xM indomethacin (Fig. 6). More- 
over, no inhibitory effect of indomethacin (up to 40 /xM) 
on arachidonic acid release was observed (not shown). In 
addition, TGFa-induced DNA synthesis was also sup- 
pressed by the specific PGHS-2 inhibitor NS-398. A dose 
of 40 /zM which inhibited PGE 2 accumulation by 80% 
(Table 1) reduced TGFa-induced DNA synthesis by 56%. 
The inhibitory effect of indomethacin on DNA synthe- 
sis depended on the dose of TGFa (Fig. 7). DNA-labeling 
stimulated with 25 ng/ml  TGFc~ was inhibited, whereas 
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Fig. 5. Effects of TGFce on the release of PGE 2 (a) and PGF2~ (b) from 
growth-arrested HaCaT cells. Cells were treated with TGFot (25 ng/ml; 
O)  or with bidistilled water (control; v ) for the times indicated, and the 
prostaglandin concentrations in the supernatants were determined by an 
immunoenzymometric assay (see in Section 2). Each point is the mean of 
two independent assays performed in duplicate with a maximum devia- 
tion of < 15%. 
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Fig. 6. Effects of indomethacin on PGF2~ release, DNA-labeling, and cytotoxicity in TGFa-treated HaCaT cells. Growth-arrested HaCaT cells were 
treated with TGFc~ (25 ng/ml)  plus indomethacin (at the concentrations indicated) for 31 h and PGF2~ accumulation i the medium (dotted line; O)  and 
DNA-labeling (solid line; • ) were measured. In parallel cultures the cytotoxicity of indomethacin was determined using the MTT-reduction-assay (solid 
line; v ; see Section 2). For DNA synthesis and PGF 2 , accumulation, each point is the mean + S.E. of 3 experiments performed in triplicate. For the MTT 
assay each point is the mean of two independent assays performed in duplicate with a maximum deviation of < 15%. 
In order to find out the indomethacin-sensitive time 
period of the TGFc~ effect, the inhibitor was added at 
different ime points before or after TGFa application (25 
ng/ml). As shown in Fig. 8, a significant inhibitory effect 
on mitogenesis was only observed when the drug was 
applied before or simultaneously with TGFcL This rather 
narrow time-window co]xelated with the rapid onset of 
prostaglandin synthesis in such cultures (Fig. 5). 
If prostaglandins mediate the mitogenic effect of higher 
TGFa doses they should be able to evoke a hyperprolifera- 
tive response by themselves. Table 2 shows that this was 
not the case: neither PGE 2 nor PGF2~ exhibited a substan- 
tial stimulatory effect on DNA synthesis in HaCaT cells, 
nor did they augment he mitogenic effect of TGFcL 
Moreover, all attempts to overcome the indomethacin- 
caused inhibition of TGFc~-induced DNA synthesis by 
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Fig. 7. TGFa-induced DNA synthesis and PGP2~ release in HaCaT cells: effect of indomethacin. Growth-arrested HaCaT cells were treated with 
increasing doses of TGPa in the presence or absence of indomethacin (40 ~M) for 31 h and the PGF z ~ content of the supernatant and DNA-labeling were 
determined as described in Section 2. Each point is the mean ± S.E. of three experiments performed in triplicate; v ,  DNA-labeling in the absence of 
indomethacin; xT, DNA-labcling in the presence of indomethacin; O, PGF2~ release in the absence of indomethacin. 
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Table 1 
Inhibition of TGFc~-induced PGE 2 accumulation by indomethacin and 
NS-398 
Additions PGE 2 
(ng/ml) 
Acetone bidist, water 0.12 5:0.02 
Acetone TGF~ 2.40 5:0.29 
Indomethacin (40/zM) bidist, water 0.06 5:0.02 
Indomethacin (1.0 /.LM) TGF~ 0.55 5:0.09 
Indomethacin (10/xM) TGF, 0.40 5:0.05 
Indomethacin (40/.tM) TGF~ 0.18 _+ 0.06 
NS-398 (40 p~M) bidist, water 0.08 5:0.04 
NS-398 (1.0 /xM) TGF,~ 2.0___0.24 
NS-398 (10 ~M) TGF,~ 0.965:0.12 
NS-398 (40 /xM) TGF,~ 0.40 5:0.06 
Growth-arrested HaCaT-cells were treated with acetone (final concentra- 
tion 0.1%) or increasing concentrations of indomethacin or NS-398 15 
min prior to bidistilled water or TGFo~ (25 ng/ml). 
PGE 2 accumulation i  the supernatant was determined by an immunoen- 
zymometric assay (see Section 2) 8 h after administration of bidistilled 
water or TGFc~. Each point is the mean -- S.E. of two independent assays 
performed in triplicate. 
Table 2 
Effect of PGE 2 and PGF2~ on DNA-labeling with or without TGFc~ (25 
ng/ml) in HaCaT-cells 
Additions Specific activity of DNA 
(cpm//zg DNA) 
Control + acetone 15.8 5:1.9 
- + PGE 2 (10 nM) 18.3 2:2.0 
- +PGE e (10/zM) 12.95:1.5 
- + PGFz, (10 nM) 19.1___0.9 
- +PGF2, ~ (10/xM) 13.95:1.2 
TGFot + acetone 35.7 5:2.8 
- + PGE~ (10 nM) 36.5 5:2.1 
- +PGE 2 (10 /xM) 34.85:1.7 
- +PGF2~ (10 nM) 38.55:2.9 
- +PGF2~ (10/zM) 35.1 5:1.1 
Growth-arrested HaCaT-cells were treated with acetone (final concentra- 
tion 0.1%) or increasing concentrations of PGE 2 and PGF2, ~ in the 
presence or absence (control) of TGFoz (25ng/ml). 
After 30 h, DNA-labeling was carried out as described in Section 2. Each 
point is the mean + S.E. of two independent assays performed in tripli- 
cate. 
prostaglandins failed completely. Such experiments were 
carried out using PGE 1, PGE 2, and PGF2~ (0,1-15 /zM) 
and PGG 2 (0.01-1 /zM), whereby the prostaglandins were 
added either 1 h prior to or simultaneously with 
TGFa/indomethacin. PGG z even augmented the in- 
hibitory effect of indomethacin ( ot shown). In addition, 
neither PGE 2 nor PGF2~ were able to overcome NS-398- 
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Fig. 8. Inhibition by indomethacin of TGF~-induced DNA synthesis as a 
function of the time point of inhibitor application. TGF~ (25 ng/ml) was 
added to the cells in fresh low-serum medium at zero time and indo- 
methacin (40 /~M) was added without a further medium change at the 
times indicated. DNA-pulse-labeling was cmTied out for I h at 30 h after 
TGF¢~ application. Each point is the mean5:S.E, of three experiments 
performed in triplicate; O, DNA labeling in the presence of TGFo~ and 
indomethacin, -  control. 
caused inhibition of TGFa-induced DNA synthesis (data 
not shown). 
4. Discussion 
Mitogenic agents, such as polypeptide growth factors, 
stimulate different signal-activated phospholipases generat- 
ing lipid-derived mediators like arachidonic acid and 
prostaglandins [23]. Such an effect has been shown for 
various cell types including keratinocytes treated with 
TGFa [10,11,13]. 
A relationship between prostaglandin formation and 
mitogenic stimulation of growth-arrested cells is indicated 
by several lines of evidence. Thus, a synergistic effect of 
prostaglandins and EGF has been observed in Swiss 3T3 
fibroblasts [20] and hepatocytes [24]. In an osteoblastic ell 
line an analogous synergism could be traced back to an 
up-regulation by PGF2~ of IGF-1 receptors [25], and for 
glomerular epithelial cells PGE 2 has been shown to en- 
hance the activation (tyrosine autophosphorylation) f the 
EGF receptor by EGF [26]. In Swiss 3T3 cells, however, 
PGF2, was found to reduce the affinity of the EGF 
receptor for EGF via protein kinase C activation [27]. In 
3T3 fibroblasts indomethacin was shown to inhibit both 
prostaglandin synthesis and EGF-induced cell proliferation 
[20,28], and this inhibition could be reversed by prosta- 
glandins. 
For keratinocytes, an essential role of prostaglandins in 
mitogenic stimulation has been firmly established by in 
vivo experiments using mice [3,4]. As far as the situation 
in cell culture is concerned, the results are more conflict- 
ing. Thus, the phorbol ester tumor promoter TPA induces 
DNA synthesis and prostaglandin formation in both mouse 
and guinea pig keratinocytes, as it does in mouse skin in 
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vivo. However, indomethacin did not inhibit the mitogenic 
activation of mouse keratinocytes [16,29], while it pre- 
vented the effect on guinea pig keratinocytes [30] and 
mouse epidermis in vivo [3], and this inhibition could be 
overcome by prostaglandin application in both cases. Us- 
ing primary human keratinocytes under different growth 
conditions, Pentland and Needleman [31 ] observed a posi- 
tive correlation between rellular proliferation and prosta- 
glandin production. Moreover, indomethacin hibited the 
increase of cell number in non-confluent cultures by up to 
40% (at a dose of 1-10 /zg/ml) when incubated for 3 
days, and PGE 2, but no other prostaglandins, overcame 
this inhibition at a dose _>_ 1 ng/ml. 
Here we have addressed the question as to whether the 
stimulatory effect of TGFc~ on growth-arrested human 
keratinocytes (HaCaT) is mediated by prostaglandins. The 
results obtained reveal a rather complex situation. As far as 
the correlation of TGFce-induced DNA synthesis and 
prostaglandin production is concerned, the cells exhibited a
biphasic response in that such a correlation was only 
observed at higher TGFa concentrations, whereas at lower 
concentrations DNA synthesis occurred in the absence of a 
significant activation of prostaglandin biosynthesis. In 
agreement with this observation, indomethacin and NS-398 
inhibited only the mitogenic effect of higher TGFa doses 
concomitantly with an inhibition of the accompanying 
prostaglandin synthesis. These results indicate the exis- 
tence of two different pathways of TGFc~-induced mito- 
genic signaling in HaCaT cells. We were unable, however, 
to unequivocally prove a mediator function of prosta- 
glandins, since the inhibitory effect of both indomethacin 
and NS-398 on TGFc~-induced DNA synthesis could not 
be overcome by applying prostaglandins together with 
TGFc~. Quite a similar situation was reported for human 
hematopoetic cells [32], human epithelial cells [33] and rat 
mammary tumor cells [34]. 
These and our results are, of course, clearly in contrast 
with the observations discussed above concerning EGF-de- 
pendent stimulation of 3"I'3 fibroblasts [20,28]. Presently, 
there is no simple explaaation for these discrepancies at 
hand. One could argue that cytotoxic effects of indo- 
methacin may have been responsible for the inhibition of 
HaCaT cells, in particu]lar since a more than 100-fold 
higher concentration of the drug was necessary for the 
inhibition of DNA synthesis than for the prevention of 
prostaglandin synthesis. But such an assumption either 
explains the inability of indomethacin to inhibit DNA 
synthesis at low TGFa concentrations (i.e., in the absence 
of prostaglandin synthes!is), nor is it consistent with the 
lack of substantial cytotoxicity of indomethacin  the dose 
range employed. The PGHS 2 inhibitor NS-398 showed a 
comparable dose dependence for both inhibition of DNA 
synthesis and prostaglandin production without overt cyto- 
toxic effects. 
Another explanation could be that in the case of HaCaT 
cells prostaglandins act as intracellular second messengers 
rather than as intercellular mediators of TGFa and that 
exogenously added prostaglandins may be unable to pene- 
trate the cells at a sufficiently high rate, in particular since 
they are strongly adsorbed by serum proteins [35]. A 
second messenger function of eicosanoids i indeed indi- 
cated by several lines of evidence [36]. 
Finally, one should consider an activation of antimitotic 
pathways by prostaglandins, which might camouflage mi- 
togenic effects, in particular under the stationary condi- 
tions of cell culture. A candidate for such an antagonistic 
pathway is the formation of cyclic AMP which is indeed 
induced by PGE 2 but not by PGF2~ in HaCaT cells (data 
not shown). Cyclic AMP is well-known for its strong 
antimitotic effect on keratinocytes [37]. Another ant- 
agonistic pathway is provided by the PGF2~-dependent 
down-regulation of EGF receptor activity as shown for 
Swiss 3T3 cells [27]. Also in HaCaT cells PGF2~ was 
found to significantly reduce the TGFa-induced autophos- 
phorylation of the receptor (unpublished results). 
Whether or not our results will help to explain the in 
vivo situation, i.e., prostaglandin-dependent hyperplastic 
transformation of epidermis, remains an open question. 
Notwithstanding the fact that an established keratinocyte 
line hardly reflects the in vivo situation in all details, one 
may conclude that TGFa-induced prostaglandin synthesis 
does not play a role at least in the early stages of hyper- 
plastic transformation, since the growth factor concentra- 
tions required may be unphysiologically high and the 
critical prostaglandin release in skin occurs much earlier 
than TGFa formation. 
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